Acute Treatment of Social Anxiety Disorder: Emerging Regulatory Landscape Facilitates Pipeline Development

Time: 8:45 am
day: Day One


  • Reviewing current chronic and acute FDA-approved and off-label drug treatment for SAD
  • Emerging regulatory landscape has paved the path for rapid development of fast-acting medications for acute treatment of SAD without the liabilities of benzodiazepines
  • The pipeline of candidates in development for acute treatment of SAD will be reviewed